ArticleLiver cancer2018
No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma.
Article in Liver cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Impact of body composition on clinical outcomes in patients with hepatocellular carcinoma: A systematic review and meta-analysis.Hepatology communications · 2026Pooled it
- Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis.Scientific reports · 2023Pooled it
- Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis.Frontiers in nutrition · 2023Pooled it
- Muscle and fat matter: Automated CT-based body composition analysis predicts survival inEuropean journal of radiology open · 2026Article
- Relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy: A meta-analysis.World journal of clinical oncology · 2025Article
- Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.Cancers · 2024Article
- Article
- Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy.Journal of hepatocellular carcinoma · 2024Article
- Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.Cancer medicine · 2023Article
- Review
- Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling.Frontiers in immunology · 2023Review
- Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.Frontiers in nutrition · 2023Article
- Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.Liver cancer · 2022Review
- Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions.World journal of gastroenterology · 2022Review
- Article
- Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma.Cancers · 2021Article
- Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis.EXCLI journal · 2021Article
- Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.Journal of gastroenterology · 2020Review
- Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients.Liver cancer · 2020Article
- Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of advanced HCC patients treated with sorafenib.
methodsWe enrolled 100 patients with advanced HCC treated with sorafenib. Prior to receiving sorafenib therapy, skeletal muscle index (SMI) and visceral fat area (VFA) were measured using computed tomography at the third lumbar vertebra and umbilical level, respectively. Muscle depletion was defined as an SMI value < 42 cm
resultsMultivariate analysis showed that having a tumor number < 7 (hazard ratio [HR] = 0.409,
conclusionsWe identified no muscle depletion with H-VFA as a novel biomarker for advanced HCC patients treated with sorafenib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.